NCT00024076

Brief Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2 lung-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2000

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2001

Completed
1.4 years until next milestone

First Posted

Study publicly available on registry

January 27, 2003

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2006

Completed
Last Updated

August 3, 2020

Status Verified

July 1, 2012

Enrollment Period

6.6 years

First QC Date

September 13, 2001

Last Update Submit

July 30, 2020

Conditions

Lung CancerMalignant MesotheliomaMetastatic CancerThymoma and Thymic Carcinoma

Keywords

recurrent non-small cell lung cancerrecurrent small cell lung cancerrecurrent malignant mesotheliomarecurrent thymoma and thymic carcinomastage IIIB non-small cell lung cancerstage IV non-small cell lung cancerpulmonary carcinoid tumorlung metastases

Interventions

radiofrequency ablationPROCEDURE

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of a primary or secondary intrathoracic malignancy
  • Any cell type or origin
  • Involving the intrapulmonary, mediastinal, or pleural/chest wall
  • Inoperable primary or metastatic cancer to the lung
  • Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
  • Single or multiple lesions that are non-contiguous with vital structures or organs such as:
  • Trachea
  • Heart
  • Aorta
  • Great vessels
  • Esophagus
  • Less than 5 cm in largest dimension
  • Accessible via percutaneous transthoracic route
  • Hepatic:
  • Coagulation profile normal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, 90095-1781, United States

Location

MeSH Terms

Conditions

Lung NeoplasmsMesothelioma, MalignantNeoplasm MetastasisThymomaCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma

Interventions

Radiofrequency Ablation

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesMesotheliomaAdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms, MesothelialPleural NeoplasmsNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms, Complex and MixedThymus NeoplasmsLymphatic DiseasesHemic and Lymphatic DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Intervention Hierarchy (Ancestors)

Radiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Robert D. Suh, MD

    Jonsson Comprehensive Cancer Center

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2001

First Posted

January 27, 2003

Study Start

May 1, 2000

Primary Completion

December 1, 2006

Last Updated

August 3, 2020

Record last verified: 2012-07

Locations

US(1)